Literature DB >> 10545801

Mitogen-activated protein kinase cascade in breast cancer.

M Maemura1, Y Iino, Y Koibuchi, T Yokoe, Y Morishita.   

Abstract

The mitogen-activated protein (MAP) kinase is considered to play a central role in diverse cellular events including carcinogenesis and tumor progression. Indeed, expression of MAP kinase, tyrosine-phosphorylated MAP kinase, and Raf-1 protein was greater in cancerous human tissues than in the surrounding noncancerous glands. In a 7,12-dimethylbenz[a]anthracene-induced rat mammary carcinoma model, estrogen promoted and ovariectomy and antiestrogen, tamoxifen (TAM) inhibited the tumor growth. Ovariectomy suppressed expression of MAP kinase, tyrosine-phosphorylated MAP kinase and Raf-1, whereas estrogen as well as TAM induced expression of MAP kinase and Raf-1 under castrated conditions. Since it was reported that MAP kinase was activated during the progression of breast carcinoma cells, such estrogenic actions of TAM toward the MAP kinase cascade might be responsible for malignant progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545801     DOI: 10.1159/000055273

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  7 in total

1.  Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation.

Authors:  James W Antoon; Melyssa R Bratton; Lori M Guillot; Scott Wadsworth; Virgilio A Salvo; Matthew E Burow
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

2.  Sustained activation of mitogen-activated protein kinases and activator protein 1 by the hepatitis B virus X protein in mouse hepatocytes in vivo.

Authors:  R Nijhara; S S Jana; S K Goswami; A Rana; S S Majumdar; V Kumar; D P Sarkar
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Doxorubicin and vinorelbine act independently via p53 expression and p38 activation respectively in breast cancer cell lines.

Authors:  A A Liem; M V C L Appleyard; M A O'Neill; T R Hupp; M P Chamberlain; A M Thompson
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

4.  Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase.

Authors:  James W Antoon; Melyssa R Bratton; Lori M Guillot; Scott Wadsworth; Virgilio A Salvo; Steven Elliott; John A McLachlan; Matthew E Burow
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

Review 5.  Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways.

Authors:  Qiang Shen; Powel H Brown
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

6.  Genetic variants in the vitamin D pathway and breast cancer disease-free survival.

Authors:  Mala Pande; Patricia A Thompson; Kim-Anh Do; Aysegul A Sahin; Christopher I Amos; Marsha L Frazier; Melissa L Bondy; Abenaa M Brewster
Journal:  Carcinogenesis       Date:  2012-11-24       Impact factor: 4.944

7.  Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition.

Authors:  James W Antoon; Ashley M Nitzchke; Elizabeth C Martin; Lyndsay V Rhodes; Seungyoon Nam; Scott Wadsworth; Virgilo A Salvo; Steven Elliott; Bridgette Collins-Burow; Kenneth P Nephew; Matthew E Burow
Journal:  Int J Oncol       Date:  2013-02-08       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.